The dip recently to once again below $4 was painful for the longs, but fortunately some of us bought even more. The funding round was coming and some insiders knew more $3.25s would be issued. I certainly hope that is the last time we'll see $3.25s - with just the $5.50 warrants above them.
The stock is impossible to trade a decent large block. Nibbling, even slightly, takes the sellers off the ask. It's been like that since it got back up above $4. Before the dip, you could hit the ask and eventually they'd lower it - getting it down so the $3.25 new warrants didn't look too much like a big give away.
The last two days have been telling. Eight weeks to get through $6 last time -- this week it took about 4k shares to breach the level. And lastly we saw a 40cent uptick in the last minute today on about 12k. The A/D line is pretty impressive.
My big question is how quickly can OCX generate meaningful revenues from international distribution and partnerships while they pursue US reimbursements? It's nice that hardly anyone follow this board b/c it means I'm ahead of the party. But can any one of the five of you reading this board talk about my question above?
I am counting on OCX having at least one announcement lined up with an international partner to be signed and released following the completion of the two outstanding validation trials. So how quickly will partnerships come once they are clear to make and sell?
With that said - I look forward to the day when we have 1000 messages on this board. Then we'll know the word is out. I am stunned by how so few folks are following or even aware of this nifty unique investment opportunity.
Good luck to all longs. We've got a phenomenal management team working for us and I for one am getting excited about how well they are delivering.
Tim
Recent OCX News
- PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace • GlobeNewswire Inc. • 05/07/2024 01:19:00 PM
- Oncocyte Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/12/2024 10:00:00 AM
- Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/12/2024 01:46:37 AM
- Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay • GlobeNewswire Inc. • 04/11/2024 09:30:00 PM
- Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 04/09/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:39:38 PM
- Oncocyte to Present at the Sequire Investor Summit in Puerto Rico • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays • GlobeNewswire Inc. • 12/06/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:19:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:05:24 PM
- Oncocyte Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/09/2023 12:00:00 PM
- Oncocyte to Announce Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/03/2023 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/12/2023 08:30:57 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 10/10/2023 08:48:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:05:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 01:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 08:05:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2023 10:57:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:50:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 11:05:36 AM
- VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients • GlobeNewswire Inc. • 07/25/2023 01:08:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 09:28:38 PM
- Oncocyte Announces 1-For-20 Reverse Stock Split • GlobeNewswire Inc. • 07/24/2023 05:35:32 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/21/2023 09:16:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/14/2023 10:03:15 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM